INGN stock forecast, quote, news & analysis
Inogen Inc is a medical technology business that focuses on respiratory health... Show more
Why Inogen (INGN) Stock Is Up +29.7% in the Last 30 Days
Key Takeaways
- Inogen shares climbed roughly +29.7% over the last 30 days, rising from a closing price of $5.14 on September 18, 2026, to about $6.67 in late October.
- The advance was driven by Inogen's announced divestiture of its U.S. oxygen rental business to Rotech Healthcare for up to $25 million, paired with a new long-term supply agreement.
- Inogen also expanded its share repurchase authorization by $15 million, bringing the total program to $45 million.
- Over the last quarter the stock is only modestly higher (about +4%), reflecting a mid-quarter pullback followed by October's sharp rebound.
- Third-quarter 2026 results are scheduled for November 5, 2026, offering the next detailed read on the company's streamlined business model.
Inogen (INGN) Company Overview and Market Position
Inogen, Inc. is a medical technology company headquartered in Beverly, Massachusetts, focused on respiratory products for the homecare setting. Its portfolio is anchored by portable oxygen concentrators (POCs), including the Inogen One and Inogen Rove systems, which deliver supplemental oxygen for patients with chronic respiratory conditions. The company has broadened its lineup with the Voxi stationary oxygen concentrator, Aurora CPAP masks for sleep apnea, and the Simeox airway-clearance device.
Inogen sells through business-to-business home medical equipment (HME) providers, a direct-to-consumer channel, and international distributors. Investors follow the stock for its exposure to the large home oxygen therapy market, its double-digit international growth, and the ramp of newer products that extend the company beyond its core POC franchise.
Inogen (INGN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Inogen shares have gained about +29.7%. The stock closed at $5.14 on September 18, 2026, and has since advanced to approximately $6.67. The move accelerated in early October: shares jumped from $5.27 on September 30 to $5.98 on October 1, a one-day rise of about +13.5% on volume of roughly 596,000 shares, well above the stock's typical daily turnover. The price continued a steady climb through mid-October.
The last quarter tells a different story on a net basis. Inogen entered the period trading around $6.40 in late July, slid to a low near $5.05–$5.14 in late September amid concerns over its U.S. sales channels, and then rebounded sharply in October. The net three-month change is about +4%, underscoring that the recent 30-day surge represents a recovery from a mid-quarter trough rather than a continuous uptrend.
What Drove INGN Stock Price in the Last 30 Days
The primary catalyst was strategic rather than operational. On September 30, 2026, Inogen announced a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare for total estimated cash consideration of up to $25 million, with the transaction expected to close in the fourth quarter of 2026. At the same time, the company signed a long-term supply agreement designed to expand patient access to Inogen oxygen concentrators through Rotech's national distribution network.
Inogen framed the divestiture as a shift toward a "simpler, more focused" commercial model intended to drive faster revenue growth and higher adjusted operating income. The rental business generated $24.3 million in revenue in the first half of 2026, a year-over-year decline of 9.8%, and will be reported as discontinued operations beginning in the third quarter. Management also increased the share repurchase authorization by $15 million to $45 million. Investors responded by re-rating the stock toward a leaner, potentially higher-margin business profile.
What Drove INGN Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by mixed second-quarter results reported on August 6, 2026. Revenue rose 3% year over year to $95.1 million, and a GAAP loss of $0.14 per share beat consensus estimates, but management cut full-year 2026 revenue guidance to a range of $355 million to $361 million, down from $366 million to $373 million. The revision reflected U.S. channel-mix pressure, with U.S. sales down 2.3% and U.S. rental revenue down 11.8% year over year, even as international sales grew 14.8%—a tenth consecutive quarter of double-digit growth. The company also raised its full-year adjusted EBITDA outlook to about $4 million, roughly 48% above 2025.
The guidance cut contributed to a summer slide that took the stock to its late-September low. The subsequent recovery has been powered by the divestiture announcement and the company's stated goal of sharpening strategic focus and improving profitability.
Trending AI Robots
For traders seeking a systematic approach to navigating moves like Inogen's, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches and find one that aligns with their own trading style and risk tolerance. The page is designed to help traders evaluate AI-driven signals without manual screening.
INGN Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Inogen's third-quarter 2026 earnings report, scheduled for November 5, 2026, which is expected to include additional detail on the rental business divestiture and its impact on the outlook for continuing operations. Key items include the initial contribution from the Rotech supply agreement, the trajectory of U.S. B2B channel growth relative to ongoing direct-to-consumer pressure, and continued traction for the Voxi and Aurora products.
Longer-term drivers include the Simeox reimbursement pathway, where the IMPACT 200 trial aims to support a case for CMS coverage, as well as potential regulatory progress in China. Sell-side coverage remains limited, with a consensus "Buy" rating and an average price target near $12.00 as of mid-October, according to aggregated analyst data. Macro factors such as healthcare reimbursement policy, medtech sector sentiment, and consumer demand for home respiratory care will also shape the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INGN in upward trend: 10-day moving average crossed above 50-day moving average on October 08, 2026
The 10-day moving average for INGN crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on INGN as a result. In 64 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
INGN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where INGN advanced for three days, in 188 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 115 of 169 cases where INGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
INGN broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. INGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.012) is normal, around the industry mean (2.923). P/E Ratio (-7.330) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.290) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.393) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical technology company
Industry MedicalNursingServices